华蟾素胶囊联合XELOX方案治疗晚期胃癌临床疗效及对患者免疫状态和血清CEA、CA19-9、MMP-14水平的影响

江冬莲; 曹仕琼; 江燕莉; 方建文

doi:10.3969/j.issn.1671-038X.2018.09.15

华蟾素胶囊联合XELOX方案治疗晚期胃癌临床疗效及对患者免疫状态和血清CEA、CA19-9、MMP-14水平的影响

- 1. 华中科技大学同济医学院附属梨园医院教学办公室, 湖北武汉 430077;
- 2. 华中科技大学同济医学院附属梨园医院消化内科, 湖北武汉 430077;
- 3. 华中科技大学同济医学院附属梨园医院内分泌科, 湖北武汉 430077

详细信息

通讯作者: 曹仕琼,E-mail:932138818@qq.com

中图分类号: R735

收稿日期: 2018-01-12

Clinical efficacy of cinobufacin capsules combined with XELOX chemotherapy in treatment of advanced gastric cancer and its effects on immune status and serum levels of CEA, CA19-9 and MMP-14

- 1. Teaching office, Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430077, China;
- 2. Department of Gastroenterology, Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430077, China;
- 3. Department of Endocrine, Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430077, China

More Information

Corresponding author: CAO Shi-qiong, E-mail: 932138818@qq.com

Received Date: 12 January 2018

摘要

摘要: [目的]探讨华蟾素胶囊联合XELOX方案治疗晚期胃癌临床疗效及对患者免疫状态和血清CEA、CA19-9、MMP-14水平的影响。[方法]回顾性分析我院2014年12月~2017年6月就诊收治的108例晚期胃癌患者临床资料，并根据治疗方式的不同分为观察组、对照组（各54例）。对照组给予单独XELOX方案化疗治疗，观察组在对照组基础上联合华蟾素胶囊治疗，比较2组患者的近期疗效、不良反应情况及治疗前后的外周血T淋巴细胞亚群、血清CEA、CA19-9、MMP-14水平变化。[结果]观察组的近期总有效率（RR：64.81%）、肿瘤控制率（DSR：85.19%）均分别高于对照组（38.89%、64.81%）（P<0.05）。治疗后2组患者CD4⁺、CD4⁺/CD8⁺、CD3⁺水平均较治疗前上升，且观察组较对照组上升明显（P<0.05），CD8⁺均较治疗前下降，且观察组较对照组下降明显（P<0.05），治疗后2组患者血清CEA、CA19-9、MMP-14水平均较治疗前降低，且观察组较对照组降低明显（P<0.05），观察组胃肠道不良反应发生率低于对照组（P<0.05）。[结论]华蟾素胶囊联合XELOX方案治疗晚期胃癌患者临床疗效显著，可有效的改善患者免疫状态，降低血清CEA、CA19-9、MMP-14水平及消化道不良反应。
- 华蟾素胶囊 /
- XELOX方案化疗 /
- 晚期胃癌疗效 /
- 免疫状态 /
- 血清CEA、CA19-9、MMP-14水平
Abstract: [Objective] To investigate the clinical efficacy of cinobufacin capsules combined with XELOX chemotherapy in treatment of advanced gastric cancer and its effects on immune status and serum levels of CEA, CA19-9 and MMP-14.[Methods] The clinical data of 108 patients with advanced gastric cancer treated in our hospital from December 2014 to June 2017 were analyzed retrospectively.And patients were divided into observation group and control group(54 cases each) according to different treatment methods.The control group was given XELOX chemotherapy alone, the observation group received cinobufacini capsules combined with XELOX chemotherapy.The short term curative effect, adverse reactions and changes of peripheral blood T lymphocyte subsets, serum CEA, CA19-9 and MMP-14 levels before and after treatment were compared between the two groups.[Results] The total effective rate(RR:64.81%) and tumor control rate(DSR:85.19%) in the observation group were significantly higher than those in the control group(38.89%, 64.81%, P<0.05).After treatment, the levels of CD4 ⁺, CD4⁺/CD8 ⁺ and CD3 ⁺ in both groups increased compared with that before treatment, and the increase level in observation group was more significant than that in control group(P<0.05).CD8⁺ in both groups decreased compared with that before treatment, and the decreased level in observation group was more significant than that in control group(P<0.05).The levels of serum CEA, CA19-9 and MMP-14 in the two groups after treatment were lower than those before treatment, and the decreased level in observation group was more significant than that in control group(P<0.05).The incidence of gastrointestinal adverse reactions in the observation group was lower than that in the control group(P<0.05).[Conclusion] The cinobufagin capsule combined with XELOX chemotherapy is effective to improve the immune status and reduce the levels of serum CEA, CA19-9 and MMP-14 and gastrointestinal adverse reactions in the treatment of advanced gastric cancer.
- Cinobufacin capsules /
- XELOX chemotherapy /
- efficacy of treating advanced gastric cancer /
- immune status /
- serum CEA,CA19-9,MMP-14 levels

HTML全文

参考文献(20)

[1]	邓峰, 张茹虎, 朱磊.奥沙利铂联合卡培他滨对中晚期胃癌患者术后化疗的疗效及对血清CA125、CEA、TPS、CYFRA21-1、CA19-9及T淋巴细胞亚群水平的影响[J].海南医学院学报, 2016, 22(17):2011-2014.
[2]	李金凤, 杜伟一, 任旭升, 等.多西他赛联合XELOX方案治疗晚期胃癌的临床研究[J].解放军医药杂志, 2017, 29(7):18-21.
[3]	谢茂高, 吴中平.复方苦参注射液对晚期胃癌化疗患者疗效、免疫功能、血清肿瘤标志物及毒副反应的观察[J].中国中西医结合消化杂志, 2016, 24(12):933-937.
[4]	邵晶, 刘敬杨, 徐睿玲, 等.注射液胸腺法新(日达仙)辅助希罗达联合奥沙利铂(XELOX方案)治疗晚期胃癌的临床疗效观察[J].现代生物医学进展, 2016, 16(23):4468-4471.
[5]	冯奉仪.实体瘤新的疗效评价标准(解读1.1版RECIST标准)[C]//中国肿瘤内科大会教育集暨.2009, 23(2):32-33.
[6]	袁云, 徐国辉.XELOX方案治疗晚期原发性肝癌的效果及对血清肿瘤标志物水平的影响[J].解放军医药杂志, 2017, 29(6):44-47.
[7]	张公正, 刘素娜, 宋秋岗.消癌平联合XELOX方案对晚期胃癌恶性分子表达的影响[J].安徽医学, 2017, 38(5):568-571.
[8]	Cui Y Y, Hui-Xia Q I, Chang G H, et al.Effect of Aidi Injection Combined with Chemotherapy on Serum Levels of HE4, CA125, CA19-9, AFP and CEA and T Cell Subsets of Patients with Ovarian Cancer[J].Prog Mod Biomed, 2017, 38(4):153-155.
[9]	田伊卿, 潘昭吉, 毛佳慧, 等.胃癌间质干细胞敲减YAP抑制胃癌的发展[J].江苏大学学报(医学版), 2017, 27(5):374-378.
[10]	蒲嘉泽, 陆鹏, 潘英.华蟾素胶囊联合NP化疗对晚期非小细胞肺癌患者血清CYFRA21-1、NSE水平及免疫功能的影响[J].湖北中医药大学学报, 2017, 19(1):26-29.
[11]	路琳, 崔秀洁, 姜北.胃癌根治术后腹腔热灌注化疗联合XELOX方案的临床效果观察[J].疑难病杂志, 2015, 13(10):1043-1046.
[12]	许彬彬, 陈志红, 汪超, 等.胃癌患者外周血IL-26的水平及其诊断价值[J].江苏大学学报(医学版), 2016, 26(5):429-432.
[13]	陈娟, 马小安, 魏丹, 等.华蟾素胶囊联合PC化疗方案对晚期非小细胞肺癌患者免疫功能、血清糖类抗原125水平及生存期的影响[J].实用心脑肺血管病杂志, 2017, 24(9):153-155.
[14]	王沁易, 沈晓宇, 马锐, 关虹, 等.重组人血管内皮抑素联合奥沙利铂及卡培他滨治疗进展期胃癌的疗效观察[J].疑难病杂志, 2016, 23(1):35-39.
[15]	张煦.BTG1蛋白在胃癌中的表达水平及临床意义[J].空军医学杂志, 2016, 32(3):171-174.
[16]	李瑞林, 许进秀, 李鲁明, 等.养正消积胶囊联合XELOX方案治疗晚期胃癌临床观察[J].中华肿瘤防治杂志, 2017, 24(12):855-857.
[17]	徐咏梅, 刘声.华蟾素胶囊联合化疗对中晚期胃癌的疗效观察[J].世界中医药, 2016, 11(7):1212-1214.
[18]	Hou J, Cui L H, Zhi-Wei W U, et al.Observation the clinical effects of improved DCF scheme and XELOX scheme in advanced gastric cancer[J].China Modern Medicine, 2016, 42(3):155-157.
[19]	周双秀, 徐莹, 周超.消癌平联合静脉化疗对晚期胃癌患者肿瘤标志分子含量及细胞活力分子表达的影响[J].海南医学院学报, 2017, 23(3):411-414.
[20]	李万刚, 崔静, 王建军, 等.支气管动脉灌注化疗联合华蟾素胶囊治疗晚期非小细胞肺癌的临床观察[J].中国药房, 2015, 25(26):3703-3706.